GNI Group Ltd
TSE:2160
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 544
3 805
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
GNI Group Ltd
Minority Interest
GNI Group Ltd
Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
GNI Group Ltd
TSE:2160
|
Minority Interest
ÂĄ2.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
||
PeptiDream Inc
TSE:4587
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Takara Bio Inc
TSE:4974
|
Minority Interest
ÂĄ312m
|
CAGR 3-Years
28%
|
CAGR 5-Years
28%
|
CAGR 10-Years
19%
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
S
|
StemRIM Inc
TSE:4599
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C
|
Cuorips Inc
TSE:4894
|
Minority Interest
ÂĄ1.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Minority Interest?
Minority Interest
2.7B
JPY
Based on the financial report for Jun 30, 2024, GNI Group Ltd's Minority Interest amounts to 2.7B JPY.
What is GNI Group Ltd's Minority Interest growth rate?
Minority Interest CAGR 10Y
10%
Over the last year, the Minority Interest growth was 50%. The average annual Minority Interest growth rates for GNI Group Ltd have been 34% over the past three years , 7% over the past five years , and 10% over the past ten years .